References
1. World Health Organisation. Fact sheet - Obesity and overweight.
Published 2020. Accessed May 20, 2020.
https://www.who.int/en/news-room/fact-sheets/detail/obesity-and-overweight
2. Adams K, Schatzkin A, Harris T, et al. Overweight, obesity, and
mortality in a large prospective cohort of persons 50 to 71 years old.N Engl J Med . 2006;(355):763-778. doi:10.1056/NEJMoa1109071
3. Bogers R, Bemelmans W, Hoogenveen R, et al. Association of Overweight
With Increased Risk of Coronary Heart Disease Partly Independent of
Blood Pressure and Cholesterol Levels. Arch Intern Med .
2007;167(16):1720-1728.
4. Sjöström L. Review of the key results from the Swedish Obese Subjects
(SOS) trial - a prospective controlled intervention study of bariatric
surgery. J Intern Med . 2013;273(3):219-234.
doi:10.1111/joim.12012
5. Sjöström L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and
cardiovascular risk factors 10 years after bariatric surgery. N
Engl J Med . Published online 2003:1695-1702.
6. Colquitt JL, Pickett K, Loveman E, Frampton GK. Surgery for weight
loss in adults. Cochrane Database of Systematic Reviews. Cochrane
Collab . 2014;(8):244.
doi:10.1002/14651858.CD003641.pub4.www.cochranelibrary.com
7. Mechanick JI, Apovian C, Brethauer S, et al. Clinical Practice
Guidelines for the Perioperative Nutrition, Metabolic, and Nonsurgical
Support of Patients Undergoing Bariatric Procedures - 2019 Update:
Cosponsored By American Association of Clinical
Endocrinologists/American College of Endocrinology,. Endocr
Pract . 2019;25(12):1346-1359. doi:10.4158/GL-2019-0406
8. Zenténius E, Andersson-Assarsson JC, Carlsson LMS, Svensson PA,
Larsson I. Self-Reported Weight-Loss Methods and Weight Change: Ten-Year
Analysis in the Swedish Obese Subjects Study Control Group.Obesity . 2018;26(7):1137-1143. doi:10.1002/oby.22200
9. Reges O, Greenland P, Dicker D, et al. Association of bariatric
surgery using laparoscopic banding, roux-en-y gastric bypass, or
laparoscopic sleeve gastrectomy vs usual care obesity management with
all-cause mortality. JAMA - J Am Med Assoc . 2018;319(3):279-290.
doi:10.1001/jama.2017.20513
10. Lindekilde N, Gladstone BP, Lübeck M, et al. The impact of bariatric
surgery on quality of life: A systematic review and meta-analysis.Obes Rev . 2015;16(8):639-651. doi:10.1111/obr.12294
11. Angrisani L, Santonicola A, Iovino P, et al. IFSO Worldwide Survey
2016: Primary, Endoluminal, and Revisional Procedures. Obes Surg .
2018;28(12):3783-3794. doi:10.1007/s11695-018-3450-2
12. Smith C, Herkes S, Behrn K, Fairbanks V, Kelly K, Sarr M. Gastric
acid secretion and vitamin B12 absorption after vertical Roux-en-Y
gastric bypass for morbid obesity. Ann Surg . 1993;218:91-96.
13. Tolone S, Savarino E, de Bortoli N, et al. Esophageal
High-Resolution Manometry Can Unravel the Mechanisms by Which Different
Bariatric Techniques Produce Different Reflux Exposures. J
Gastrointest Surg . 2020;24(1):1-7. doi:10.1007/s11605-019-04406-7
14. Yska JP, Van Der Meer DH, Dreijer AR, et al. Influence of bariatric
surgery on the use of medication. Eur J Clin Pharmacol .
2016;72(2):203-209. doi:10.1007/s00228-015-1971-3
15. Johnson TN, Bonner JJ, Tucker GT, Turner DB, Jamei M. Development
and applications of a physiologically-based model of paediatric oral
drug absorption. Eur J Pharm Sci . 2018;115(December 2017):57-67.
doi:10.1016/j.ejps.2018.01.009
16. Kostewicz ES, Aarons L, Bergstrand M, et al. PBPK models for the
prediction of in vivo performance of oral dosage forms. Eur J
Pharm Sci . 2014;57(1):300-321. doi:10.1016/j.ejps.2013.09.008
17. Darwich AS, Henderson K, Burgin A, et al. Trends in oral drug
bioavailability following bariatric surgery: Examining the variable
extent of impact on exposure of different drug classes. Br J Clin
Pharmacol . 2012;74(5):774-787. doi:10.1111/j.1365-2125.2012.04284.x
18. Azran C, Wolk O, Zur M, et al. Oral drug therapy following bariatric
surgery: an overview of fundamentals, literature and clinical
recommendations. Obes Rev . 2016;17(11):1050-1066.
doi:10.1111/obr.12434
19. van Beek AP, Emous M, Laville M, Tack J. Dumping syndrome after
esophageal, gastric or bariatric surgery: pathophysiology, diagnosis,
and management. Obes Rev . 2017;18(1):68-85. doi:10.1111/obr.12467
20. Montanha MC, Santos Magon TF, Souza Alcantara C, et al. Reduced
bioavailability of oral amoxicillin tablets compared to suspensions in
Roux‐en‐Y gastric bypass bariatric subjects. Br J Clin Pharmacol .
2019;85(9):2118-2125. doi:10.1111/bcp.14023
21. Schulman AR, Chan WW, Devery A, Ryan MB, Thompson CC. Opened Proton
Pump Inhibitor Capsules Reduce Time to Healing Compared With Intact
Capsules for Marginal Ulceration Following Roux-en-Y Gastric Bypass.Clin Gastroenterol Hepatol . 2017;15(4):494-500.e1.
doi:10.1016/j.cgh.2016.10.015
22. Lloret-Linares C, Luo H, Rouquette A, et al. The effect of morbid
obesity on morphine glucuronidation. Pharmacol Res .
2017;118:64-70. doi:10.1016/j.phrs.2016.08.031
23. Brill MJ, Van Rongen A, Van Dongen EP, et al. The Pharmacokinetics
of the CYP3A Substrate Midazolam in Morbidly Obese Patients before and
One Year after Bariatric Surgery. Pharm Res .
2015;32(12):3927-3936. doi:10.1007/s11095-015-1752-9
24. Mechanick JI, Youdim A, Jones DB, T G, L HD, Mcmahon M. Clinical
Practice Guidelines for the Perioperative Nutritional. Obesity .
2013;21(0 1):S1-27. doi:10.1002/oby.20461.Clinical
25. Carr WRJ, Mahawar KK, Balupuri S, Small PK. An evidence-based
algorithm for the management of marginal ulcers following Roux-en-Y
gastric bypass. Obes Surg . 2014;24(9):1520-1527.
doi:10.1007/s11695-014-1293-z
26. Hogben CAM, Schanker LS, Tocco DJ, Brodie BB. ABSORPTION OF DRUGS
FROM THE STOMACH. II. THE HUMAN. J Pharmacol Exp Ther .
1957;120(4).
27. Mitrov-Winkelmolen L, van Buul-Gast MCW, Swank DJ, Overdiek HWPM,
van Schaik RHN, Touw DJ. The Effect of Roux-en-Y Gastric Bypass Surgery
in Morbidly Obese Patients on Pharmacokinetics of (Acetyl)Salicylic Acid
and Omeprazole: the ERY-PAO Study. Obes Surg .
2016;26(9):2051-2058. doi:10.1007/s11695-016-2065-8
28. Walravens J, Brouwers J, Spriet I, Tack J, Annaert P, Augustijns P.
Effect of pH and Comedication on Gastrointestinal Absorption of
Posaconazole. Clin Pharmacokinet . 2011;50(11):725-734.
doi:10.2165/11592630-000000000-00000
29. Krishna G, Moton A, Lei M, Medlock MM, McLeod J. Pharmacokinetics
and absorption of posaconazole oral suspension under various gastric
conditions in healthy volunteers. Antimicrob Agents Chemother .
2009;53(3):958-966. doi:10.1128/AAC.01034-08
30. Gesquiere I, Hens B, Van der Schueren B, et al. Drug disposition
before and after gastric bypass: fenofibrate and posaconazole. Br
J Clin Pharmacol . 2016;60:1325-1332. doi:10.1111/bcp.13054
31. Carswell KA, Vincent RP, Belgaumkar AP, et al. The Effect of
Bariatric Surgery on Intestinal Absorption and Transit Time. Obes
Surg . 2014;24(5):796-805. doi:10.1007/s11695-013-1166-x
32. Dirksen C, Damgaard M, Bojsen-Møller KN, et al. Fast pouch emptying,
delayed small intestinal transit, and exaggerated gut hormone responses
after Roux-en-Y gastric bypass. Neurogastroenterol Motil .
2013;25(4). doi:10.1111/nmo.12087
33. Nguyen NQ, Debreceni TL, Burgstad CM, et al. Effects of Posture and
Meal Volume on Gastric Emptying, Intestinal Transit, Oral Glucose
Tolerance, Blood Pressure and Gastrointestinal Symptoms After Roux-en-Y
Gastric Bypass. Obes Surg . 2015;25(8):1392-1400.
doi:10.1007/s11695-014-1531-4
34. Wang G, Agenor K, Pizot J, et al. Accelerated Gastric Emptying but
No Carbohydrate Malabsorption 1 Year After Gastric Bypass Surgery (GBP).Obes Surg . 2012;22(8):1263-1267. doi:10.1007/s11695-012-0656-6
35. Yska JP, Wanders JTM, Odigie B, et al. Effect of Roux-en-Y gastric
bypass on the bioavailability of metoprolol from immediate and
controlled release tablets: A single oral dose study before and after
surgery. Eur J Hosp Pharm . Published online 2019:1-6.
doi:10.1136/ejhpharm-2018-001804
36. Gesquiere I, Darwich AS, Van der Schueren B, et al. Drug disposition
and modelling before and after gastric bypass: immediate and
controlled-release metoprolol formulations. Br J Clin Pharmacol .
2015;80(5):1021-1030. doi:10.1111/bcp.12666
37. Krieger CA, Cunningham JL, Reid JM, et al. Comparison of
Bioavailability of Single-Dose Extended-Release Venlafaxine Capsules in
Obese Patients Before and After Gastric Bypass Surgery.Pharmacotherapy . 2017;37(11):1374-1382. doi:10.1002/phar.2022
38. Hachon L, Reis R, Labat L, et al. Morphine and metabolites plasma
levels after administration of sustained release morphine in Roux-en-Y
gastric bypass subjects versus matched control subjects. Surg Obes
Relat Dis . 2017;13(11):1869-1874. doi:10.1016/j.soard.2017.07.030
39. Dobner J, Kaser S. Body mass index and the risk of infection - from
underweight to obesity. Clin Microbiol Infect . 2018;24(1):24-28.
doi:10.1016/j.cmi.2017.02.013
40. Huttunen R, Syrjänen J. Obesity and the risk and outcome of
infection. Int J Obes . 2013;37(3):333-340.
doi:10.1038/ijo.2012.62
41. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect
Dis . 2006;6(7):438-446. doi:10.1016/S1473-3099(06)70523-0
42. Brill MJE, Houwink API, Schmidt S, et al. Reduced subcutaneous
tissue distribution of cefazolin in morbidly obese versus non-obese
patients determined using clinical microdialysis. J Antimicrob
Chemother . 2014;69(3):715-723. doi:10.1093/jac/dkt444
43. Hollenstein UM, Brunner M, Schmid R, Müller M. Soft tissue
concentrations of ciprofloxacin in obese and lean subjects following
weight-adjusted dosing. Int J Obes . 2001;25(3):354-358.
doi:10.1038/sj.ijo.0801555
44. Miskowiak J, Andersen B, Nielsen VG. Absorption of oral penicillin
before and after gastroplasty for morbid obesity. Pharmacology .
1985;31(2):115-120. doi:10.1159/000138106
45. Terry SI, Gould JC, McManus JPA, Prescott LF. Absorption of
penicillin and paracetamol after small intestinal bypass surgery.Eur J Clin Pharmacol . 1982;23(3):245-248. doi:10.1007/BF00547562
46. Montanha MC, dos Santos Magon TF, de Souza Alcantara C, et al.
Reduced bioavailability of oral amoxicillin tablets compared to
suspensions in Roux-en-Y gastric bypass bariatric subjects. Br J
Clin Pharmacol . 2019;85(9):2118-2125. doi:10.1111/bcp.14023
47. Rocha MBS, De Nucci G, Lemos FN, et al. Impact of Bariatric Surgery
on the Pharmacokinetics Parameters of Amoxicillin. Obes Surg .
2019;29(3):917-927. doi:10.1007/s11695-018-3591-3
48. Kampmann JP, Klein H, Lumholtz B, Hansen JEM. Ampicillin and
Propylthiouracil Pharmacokinetics in Intestinal Bypass Patients Followed
Up to a Year after Operation. Clin Pharmacokinet .
1984;9(2):168-176. doi:10.2165/00003088-198409020-00004
49. Prince RA, Pincheira JC, Mason EE, Printen KJ. Influence of
bariatric surgery on erythromycin absorption. J Clin Pharmacol .
1984;24(11-12):523-527. doi:10.1002/j.1552-4604.1984.tb02762.x
50. Padwal RS, Ben-Eltriki M, Wang X, et al. Effect of gastric bypass
surgery on azithromycin oral bioavailability. J Antimicrob
Chemother . 2012;67(9):2203-2206. doi:10.1093/jac/dks177
51. De Smet J, Colin P, De Paepe P, et al. Oral bioavailability of
moxifloxacin after Roux-en-Y gastric bypass surgery. J Antimicrob
Chemother . 2012;67(1):226-229. doi:10.1093/jac/dkr436
52. Rivas AB, Lopez-Picado A, Salas-Butrón M del R, et al. Effect of
Roux-en-Y gastric surgery on ciprofloxacin pharmacokinetics: an obvious
effect? Eur J Clin Pharmacol . 2019;75(5):647-654.
doi:10.1007/s00228-018-02623-8
53. Roy DJ, Langworthy DR, Thurber KM, Lorentz PA, Dierkhising RA, Mundi
MS. Comparison of oral antibiotic failure rates in post-Roux-en-Y
gastric bypass patients versus controls. Surg Obes Relat Dis .
2017;13(9):1524-1529. doi:10.1016/j.soard.2017.03.026
54. Madlensky L, Natarajan L, Tchu S, et al. Tamoxifen metabolite
concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin
Pharmacol Ther . 2011;89(5):718-725. doi:10.1038/clpt.2011.32
55. Jager NGL, Rosing H, Schellens JHM, Linn SC, Beijnen JH. Tamoxifen
dose and serum concentrations of tamoxifen and six of its metabolites in
routine clinical outpatient care. Breast Cancer Res Treat .
2014;143(3):477-483. doi:10.1007/s10549-013-2826-1
56. Binkhorst L, Van Gelder T, Mathijssen RHJ. Individualization of
tamoxifen treatment for breast carcinoma. Clin Pharmacol Ther .
2012;92(4):431-433. doi:10.1038/clpt.2012.94
57. Wills SM, Zekman R, Bestul D, Kuwajerwala N, Decker D. Tamoxifen
Malabsorption after Roux-en-Y Gastric Bypass Surgery: Case Series and
Review of the Literature. Pharmacotherapy . 2010;30(2):217.
doi:10.1592/phco.30.2.217
58. Jager NGL, Koornstra RHT, Vincent AD, et al. Hot flashes are not
predictive for serum concentrations of tamoxifen and its metabolites.BMC Cancer . 2013;13. doi:10.1186/1471-2407-13-612
59. Bauer KA. Pros and cons of new oral anticoagulants. Hematol am
soc hematol educ Progr . Published online 2013:464-470.
60. Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of food, an
antacid, and the H2 antagonist ranitidine on the absorption of BAY
59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy
subjects. J Clin Pharmacol . 2006;46(5):549-558.
doi:10.1177/0091270006286904
61. Dewald TA, Becker RC. The pharmacology of novel oral anticoagulants.J Thromb Thrombolysis . 2014;37(2):217-233.
doi:10.1007/s11239-013-0967-z
62. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic Profile of
the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy
Volunteers and Patients Undergoing Total Hip Replacement. J Clin
Pharmacol . 2005;45(5):555-565. doi:10.1177/0091270005274550
63. Martin KA, Lee CR, Farrell TM, Moll S. Oral Anticoagulant Use After
Bariatric Surgery: A Literature Review and Clinical Guidance. Am J
Med . 2017;130(5):517-524. doi:10.1016/j.amjmed.2016.12.033
64. Kröll D, Stirnimann G, Vogt A, et al. Pharmacokinetics and
pharmacodynamics of single doses of rivaroxaban in obese patients prior
to and after bariatric surgery. Br J Clin Pharmacol .
2017;83(7):1466-1475. doi:10.1111/bcp.13243
65. Kröll D, Nett PC, Borbély YM, et al. The effect of bariatric surgery
on the direct oral anticoagulant rivaroxaban: the extension study.Surg Obes Relat Dis . 2018;14(12):1890-1896.
doi:10.1016/j.soard.2018.08.025
66. Rottenstreich A, Barkai A, Arad A, Raccah BH, Kalish Y. The effect
of bariatric surgery on direct-acting oral anticoagulant drug levels.Thromb Res . 2018;163:190-195. doi:10.1016/j.thromres.2017.11.006
67. Lachant DJ, Uraizee I, Gupta R, Pedulla AJ. IJCRI International
Journal of Case Reports and Images. Int J Case Reports Images
Cover . 2015;6(11):663-664. doi:10.1681/ASN.2014100997
68. Lee D, DeFilipp Z, Judson K, Kennedy M. Subtherapeutic
anticoagulation with dabigatran following Roux-en-Y gastric bypass
surgery. J Cardiol Cases . 2013;8(1):e49-e50.
doi:10.1016/j.jccase.2013.03.013
69. Miklič M, Mavri A, Vene N, et al. Intra- and inter- individual
rivaroxaban concentrations and potential bleeding risk in patients with
atrial fibrillation. Eur J Clin Pharmacol . 2019;75(8):1069-1075.
doi:10.1007/s00228-019-02693-2
70. Ruff CT, Giugliano RP, Braunwald E, et al. Association between
edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: An
analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48
trial. Lancet . 2015;385(9984):2288-2295.
doi:10.1016/S0140-6736(14)61943-7
71. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran
plasma concentrations and patient characteristics on the frequency of
ischemic stroke and major bleeding in atrial fibrillation patients: The
RE-LY trial (Randomized Evaluation of Long-Term Anticoagulation
Therapy). J Am Coll Cardiol . 2014;63(4):321-328.
doi:10.1016/j.jacc.2013.07.104
72. Gosselin R, Grant RP, Adcock DM. Comparison of the effect of the
anti-Xa direct oral anticoagulants apixaban, edoxaban, and rivaroxaban
on coagulation assays. Int J Lab Hematol . 2016;38(5):505-513.
doi:10.1111/ijlh.12528
73. Cini M, Legnani C, Padrini R, et al. DOAC plasma levels measured by
chromogenic anti-Xa assays and HPLC-UV in apixaban- and
rivaroxaban-treated patients from the START-Register. Int J Lab
Hematol . 2020;42(2):214-222. doi:10.1111/ijlh.13159
74. Kubitza D, Willmann S, Becka M, et al. Exploratory evaluation of
pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children
and adolescents: An EINSTEIN-Jr phase i study. Thromb J .
2018;16(1):1-13. doi:10.1186/s12959-018-0186-0
75. Kassir R, Debs T, Blanc P, et al. Complications of bariatric
surgery: Presentation and emergency management. Int J Surg .
2016;27:77-81. doi:10.1016/j.ijsu.2016.01.067
76. Thereaux J, Lesuffleur T, Czernichow S, et al. Long-term adverse
events after sleeve gastrectomy or gastric bypass: a 7-year nationwide,
observational, population-based, cohort study. Lancet Diabetes
Endocrinol . 2019;7(10):786-795. doi:10.1016/S2213-8587(19)30191-3
77. Dallal RM, Bailey LA. Ulcer disease after gastric bypass surgery.Surg Obes Relat Dis . 2006;2(4):455-459.
doi:10.1016/j.soard.2006.03.004
78. D’Hondt MA, Pottel H, Devriendt D, Van Rooy F, Vansteenkiste F. Can
a short course of prophylactic low-dose proton pump inhibitor therapy
prevent stomal ulceration after laparoscopic Roux-en-Y gastric bypass?Obes Surg . 2010;20(5):595-599. doi:10.1007/s11695-009-0062-x
79. Gumbs AA, Duffy AJ, Bell RL. Incidence and management of marginal
ulceration after laparoscopic Roux-Y gastric bypass. Surg Obes
Relat Dis . 2006;2(4):460-463. doi:10.1016/j.soard.2006.04.233
80. Wu Chao Ying V, Song SH, J. Khan K, et al. Prophylactic PPI help
reduce marginal ulcers after gastric bypass surgery: a systematic review
and meta-analysis of cohort studies. Surg Endosc .
2015;29(5):1018-1023. doi:10.1007/s00464-014-3794-1
81. Garrido AB, Rossi M, Lima SE, Brenner AS, Gomes CAR. Early marginal
ulcer following Roux-en-Y gastric bypass under proton pump inhibitor
treatment - Prospective multicentric study. Arq Gastroenterol .
2010;47(2):130-134. doi:10.1590/S0004-28032010000200003
82. Kang X, Zurita-Macias L, Hong D, Cadeddu M, Anvari M, Gmora S. A
comparison of 30-day versus 90-day proton pump inhibitor therapy in
prevention of marginal ulcers after laparoscopic Roux-en-Y gastric
bypass. Surg Obes Relat Dis . 2016;12(5):1003-1007.
doi:10.1016/j.soard.2015.11.010
83. Coblijn UK, Lagarde SM, De Castro SMM, Kuiken SD, Van Tets WF, Van
Wagensveld BA. The influence of prophylactic proton pump inhibitor
treatment on the development of symptomatic marginal ulceration in
Roux-en-Y gastric bypass patients: A historic cohort study. Surg
Obes Relat Dis . 2016;12(2):246-252. doi:10.1016/j.soard.2015.04.022
84. Plaeke P, Ruppert M, Hubens G. Benefits of prophylactic proton pump
inhibitors after Roux-en-Y gastric bypass surgery a retrospective study.Acta Chir Belg . 2015;115(4):273-278.
doi:10.1080/00015458.2015.11681111
85. Hakkarainen TW, Steele SR, Bastaworous A, et al. Nonsteroidal
anti-inflammatory drugs and the risk for anastomotic failure A report
from Washington State’s Surgical Care and Outcomes Assessment Program
(SCOAP). JAMA Surg . 2015;150(3):223-228.
doi:10.1001/jamasurg.2014.2239
86. Sasse KC, Ganser J, Kozar M, et al. Seven cases of gastric
perforation in Roux-en-Y gastric bypass patients: What lessons can we
learn? Obes Surg . 2008;18(5):530-534.
doi:10.1007/s11695-007-9335-4
87. Wendling MR, Linn JG, Keplinger KM, et al. Omental patch repair
effectively treats perforated marginal ulcer following Roux-en-Y gastric
bypass. Surg Endosc . 2013;27(2):384-389.
doi:10.1007/s00464-012-2492-0
88. Yska JP, Gertsen S, Flapper G, Emous M, Wilffert B, van Roon EN.
NSAID Use after Bariatric Surgery: a Randomized Controlled Intervention
Study. Obes Surg . 2016;26(12):2880-2885.
doi:10.1007/s11695-016-2218-9
89. Gambineri A, Laudisio D, Marocco C, Radellini S, Colao A, Savastano
S. Female infertility: which role for obesity? Int J Obes Suppl .
2019;9(1):65-72. doi:10.1038/s41367-019-0009-1
90. Merhi ZO. Impact of bariatric surgery on female reproduction.Fertil Steril . 2009;92(5):1501-1508.
doi:10.1016/j.fertnstert.2009.06.046
91. Dao T, Kuhn J, Ehmer D, Fisher T, McCarty T. Pregnancy outcomes
after gastric-bypass surgery. Am J Surg . 2006;192(6):762-766.
doi:10.1016/j.amjsurg.2006.08.041
92. Wittgrove AC, Jester L, Wittgrove P, Clark W. Pregnancy following
gastric by-pass for morbid obesity. Obes Surg . 1998;8:461-464.
93. Patel JA, Patel NA, Thomas RL, Nelms JK, Colella JJ. Pregnancy
outcomes after laparoscopic Roux-en-Y gastric bypass. Surg Obes
Relat Dis . 2008;4(1):39-45. doi:10.1016/j.soard.2007.10.008
94. Victor A, Odlind V, Kral J. Oral contraceptive absorption and sex
hormone binding globulins in obese women: effects of jejunoileal bypass.Gastroenterol Clin North Am . 1987;(16(3)):483-491.
95. Gerrits E, Ceulemans R, van Hee R, Hendrickx L, Totté E. Materials
and MethoContraceptive Treatment after Biliopancreatic Diversion Needs
Consensusds. Obes Surg . 2003;13:378-382.
96. Ciangura C, Corigliano N, Basdevant A, et al. Etonorgestrel
concentrations in morbidly obese women following Roux-en-Y gastric
bypass surgery: Three case reports. Contraception .
2011;84(6):649-651. doi:10.1016/j.contraception.2011.03.015
97. Damhof MA, Pierik E, Krens LL, Vermeer M, van Det MJ, van Roon EN.
Assessment of Contraceptive Counseling and Contraceptive Use in Women
After Bariatric Surgery. Obes Surg . 2019;29(12):4029-4035.
doi:10.1007/s11695-019-04084-z
98. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp
CW. Obesity is associated with poor response to clopidogrel and an
increased susceptibility to protease activated receptor-1 mediated
platelet activation. Transl Res . 2013;161(5):421-429.
doi:10.1016/j.trsl.2012.12.015
99. Tamminen M, Lassila R, Westerbacka J, Vehkavaara S, Yki-Järvinen H.
Obesity is associated with impaired platelet-inhibitory effect of
acetylsalicylic acid in nondiabetic subjects. Int J Obes .
2003;27(8):907-911. doi:10.1038/sj.ijo.0802312
100. Bordeaux BC, Qayyum R, Yanek LR, et al. Effect of obesity on
platelet reactivity and response to low-dose aspirin. Prev
Cardiol . 2010;13(2):56-62. doi:10.1111/j.1751-7141.2009.00058.x
101. Larsen SB, Grove EL, Neergaard-Petersen S, Würtz M, Hvas AM,
Kristensen SD. Determinants of reduced antiplatelet effect of aspirin in
patients with stable coronary artery disease. PLoS One .
2015;10(5):1-14. doi:10.1371/journal.pone.0126767
102. Norgard NB, Monte S V., Fernandez SF, Ma Q. Aspirin responsiveness
changes in obese patients following bariatric surgery. Cardiovasc
Ther . 2017;35(4):2-6. doi:10.1111/1755-5922.12268
103. Norgard NB. Obesity and Altered Aspirin Pharmacology. Clin
Pharmacokinet . 2018;57(6):663-672. doi:10.1007/s40262-017-0611-8
104. Cohen HW, Crandall JP, Hailpern SM, Billett HH. Aspirin resistance
associated with HbA1c and obesity in diabetic patients. J Diabetes
Complications . 2008;22(3):224-228. doi:10.1016/j.jdiacomp.2007.05.002
105. Darlington A, Tello-Montoliu A, Rollini F, et al. Pharmacodynamic
effects of standard dose prasugrel versus high dose clopidogrel in
non-diabetic obese patients with coronary artery disease. Thromb
Haemost . 2013;111(2):258-265. doi:10.1160/TH13-07-0529
106. Bonello-Palot N, Armero S, Paganelli F, et al. Relation of Body
Mass Index to High On-Treatment Platelet Reactivity and of Failed
Clopidogrel Dose Adjustment According to Platelet Reactivity Monitoring
in Patients Undergoing Percutaneous Coronary Intervention. Am J
Cardiol . 2009;104(11):1511-1515. doi:10.1016/j.amjcard.2009.07.015
107. Sibbing D, von Beckerath O, Schömig A, Kastrati A, von Beckerath N.
Impact of Body Mass Index on Platelet Aggregation After Administration
of a High Loading Dose of 600 mg of Clopidogrel Before Percutaneous
Coronary Intervention. Am J Cardiol . 2007;100(2):203-205.
doi:10.1016/j.amjcard.2007.02.081
108. Kang X, Hong D, Anvari M, Tiboni M, Amin N, Gmora S. Is Daily
Low-Dose Aspirin Safe to Take Following Laparoscopic Roux-en-Y Gastric
Bypass for Obesity Surgery? Obes Surg . 2017;27(5):1261-1265.
doi:10.1007/s11695-016-2462-z
109. Ma Q., Norgard N. MS. Abstract, ACCP Annual Meeting 2017.
Pharmacotherapy 2017 37:12 (e142-). Pharmacother J Hum Pharmacol
Drug Ther . 2017;37(12):e124-e238. doi:10.1002/phar.2052
110. Caruana JA, McCabe MN, Smith AD, Panemanglore VP, Sette Camara D.
Risk of massive upper gastrointestinal bleeding in gastric bypass
patients taking clopidogrel. Surg Obes Relat Dis .
2007;3(4):443-445. doi:10.1016/j.soard.2006.12.008
111. Steinemann DC, Bueter M, Schiesser M, Amygdalos I, Clavien PA,
Nocito A. Management of anastomotic ulcers after Roux-en-Y gastric
bypass: Results of an international survey. Obes Surg .
2014;24(5):741-746. doi:10.1007/s11695-013-1152-3
112. Wilson JA, Romagnuolo J, Byrne TK, Morgan K, Wilson FA. Predictors
of endoscopic findings after Roux-en-Y gastric bypass. Am J
Gastroenterol . 2006;101(10):2194-2199.
doi:10.1111/j.1572-0241.2006.00770.x
113. Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R.
Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric
bypass recipients. Ann Surg . 2013;258(2):262-269.
doi:10.1097/SLA.0b013e31827a0e82
114. Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: A
comprehensive review. Gut Liver . 2017;11(1):27-37.
doi:10.5009/gnl15502
115. Rajan TM, Menon V. Psychiatric disorders and obesity: A review of
association studies. J Postgrad Med . 2017;63(3):182-190.
doi:10.4103/jpgm.JPGM_712_16
116. Seaman JS, Bowers SP, Dixon P, Schindler L. Dissolution of
Common Psychiatric Medications in a Roux-En-Y Gastric Bypass Model . Vol
46.; 2005.
117. Hamad GG, Helsel JC, Perel JM, et al. The Effect of Gastric Bypass
on the Pharmacokinetics of Serotonin Reuptake Inhibitors. Am J
Psychiatry . 2012;169(3):256-263. doi:10.1176/appi.ajp.2011.11050719
118. Marzinke MA, Petrides AK, Steele K, et al. Decreased Escitalopram
Concentrations Post-Roux-en-Y Gastric Bypass Surgery. Ther Drug
Monit . 2015;37:408-412.
119. Roerig JL, Steffen K, Zimmerman C, Mitchell JE, Crosby RD, Cao L.
Preliminary comparison of sertraline levels in postbariatric surgery
patients versus matched nonsurgical cohort. Surg Obes Relat Dis .
2012;8(1):62-66. doi:10.1016/j.soard.2010.12.003
120. Roerig JL, Steffen KJ, Zimmerman C, Mitchell JE, Crosby RD, Cao L.
A comparison of duloxetine plasma levels in postbariatric surgery
patients versus matched nonsurgical control subjects. J Clin
Psychopharmacol . 2013;33(4):479-484. doi:10.1097/JCP.0b013e3182905ffb
121. Strong AT, Sharma G, Nor Hanipah Z, et al. Adjustments to warfarin
dosing after gastric bypass and sleeve gastrectomy. Surg Obes
Relat Dis . 2018;14(5):700-706. doi:10.1016/j.soard.2017.12.021
122. Steffen KJ, Wonderlich JA, Erickson AL, Strawsell H, Mitchell JE,
Crosby RD. Comparison of warfarin dosages and international normalized
ratios before and after Roux-en-Y gastric bypass surgery.Pharmacotherapy . 2015;35(9):876-880. doi:10.1002/phar.1632
123. Schullo-Feulner AM, Stoecker Z, Brown GA, Schneider J, Jones TA,
Burnett B. Warfarin dosing after bariatric surgery: a retrospective
study of 10 patients previously stable on chronic warfarin therapy.Clin Obes . 2014;4(2):108-115. doi:10.1111/cob.12046
124. Irwin AN, McCool KH, Delate T, Witt DM. Assessment of warfarin
dosing requirements after bariatric surgery in patients requiring
long-term warfarin therapy. Pharmacotherapy .
2013;33(11):1175-1183. doi:10.1002/phar.1307
125. Wallace JL, Reaves AB, Tolley EA, et al. Comparison of initial
warfarin response in obese patients versus non-obese patients. J
Thromb Thrombolysis . 2013;36(1):96-101. doi:10.1007/s11239-012-0811-x